Answers are grounded in this paper and cite their sources.
Clinical trial reveals durvalumab plus platinum chemotherapy failed primary endpoints in upper tract urothelial carcinoma, suggesting tumor downstaging benefits without added surgical risk.
Although our negative study did not meet its primary end point in either cohort, the combination of durvalumab and platin-based chemotherapy, especially cisplatin, showed promising results in terms of downstaging. The safety profile was good and the surgical risk was not increased.
No takes yet. Share an insight, caveat, or question.
Houédé et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: